Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues

Oncotarget

Volumn 7, Issue 35, 2016, Pages 56842-56854

  Chen, Wei ^a,b   Zhou, Jiancheng ^c   Wu, Kaijie ^a   Huang, Jun ^a   Ding, Ye ^d   Yun, Eun Jin ^b   Wang, Bin ^a,b   Ding, Chunyong ^d   Hernandez, Elizabeth ^b   Santoyo, John ^b   Chen, Haiying ^d   Lin, Ho ^e   Sagalowsky, Arthur ^b   He, Dalin ^a   Zhou, Jia ^d   Hsieh, Jer Tsong ^b,f  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^d University of Texas Medical Branch School of Medicine   (United States)

^e NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Oridonin; Transitional cell carcinoma; Wnt pathway; XBP1; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYD 6 17; MESSENGER RNA; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; CTNNB1 PROTEIN, HUMAN; KAURANE DERIVATIVE; ORIDONIN; WNT PROTEIN; XBP1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BETA CATENIN GENE; BLADDER CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; GENE EXPRESSION REGULATION; IC50; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TRANSITIONAL CELL CARCINOMA; ANIMAL; BIOLOGY; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; METABOLISM; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BETA CATENIN; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DITERPENES, KAURANE; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MICE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; WNT PROTEINS; X-BOX BINDING PROTEIN 1;

EID: 84984878615     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10863     Document Type: Article

References (43)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
2. Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European urology. 2005; 48:202-205; discussion 205-206.
3. Froehner M, Koch R, Heberling U, Novotny V, Oehlschlaeger S, Hubler M, Baretton GB, Hakenberg OW, Wirth MP. Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. European urology. 2015.
4. Karam JA, Huang S, Fan J, Stanfield J, Schultz RA, Pong RC, Sun X, Mason RP, Xie XJ, Niu G, Chen X, Frenkel EP, Sagalowsky AI, Hsieh JT. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. International journal of cancer. 2011; 128:2823-2832.
5. Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, Guo P, Li L, Wang X, He D. Silibinin inhibits beta-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cellular signalling. 2013; 25:2625-2633.
6. Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL, Chan KS. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015; 517:209-213.
7. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J, Jr., Chang HY, van de Rijn M, Shortliffe L, Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:14016-14021.
8. Chan KS, Volkmer JP, Weissman I. Cancer stem cells in bladder cancer: a revisited and evolving concept. Current opinion in urology. 2010; 20:393-397.
9. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clinical and translational medicine. 2013; 2:3.
10. Owona BA, Schluesener HJ. Molecular Insight in the Multifunctional Effects of Oridonin. Drugs in R&D. 2015; 15:233-244.
11. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. The FEBS journal. 2014; 281:1750-1758.
12. Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Strobel P, Langer R, Keller G, Rocken C, Zimmermann W, Schmid RM, Ebert MP, Burgermeister E. WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene. 2013; 32:375-387.
13. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/betacatenin-ATP-binding cassette G2 signaling. Oncogene. 2013; 32:2767-2781.
14. Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt/betacatenin signaling in drug resistance of pancreatic cancer. Current pharmaceutical design. 2012; 18:2464-2471.
15. Xie Q, Chen L, Shan X, Shan X, Tang J, Zhou F, Chen Q, Quan H, Nie D, Zhang W, Huang AL, Tang N. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway. International journal of cancer. 2014; 135:635-646.
16. Noda T, Nagano H, Takemasa I, Yoshioka S, Murakami M, Wada H, Kobayashi S, Marubashi S, Takeda Y, Dono K, Umeshita K, Matsuura N, Matsubara K, Doki Y, Mori M, Monden M. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. British journal of cancer. 2009; 100:1647-1658.
17. Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph JM, Muhlethaler-Mottet A, Gross N. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene. 2009; 28:2245-2256.
18. De Toni F, Racaud-Sultan C, Chicanne G, Mas VM, Cariven C, Mesange F, Salles JP, Demur C, Allouche M, Payrastre B, Manenti S, Ysebaert L. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene. 2006; 25:3113-3122.
19. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009; 374:239-249.
20. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nature reviews Cancer. 2008; 8:193-204.
21. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 2007; 109:3441-3450.
22. Yoshida H, Oku M, Suzuki M, Mori K. pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. The Journal of cell biology. 2006; 172:565-575.
23. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Longterm survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of clinical oncology. 2005; 23:4602-4608.
24. Kates M, Sopko NA, Matsui H, Drake CG, Hahn NM, Bivalacqua TJ. Immune checkpoint inhibitors: a new frontier in bladder cancer. World journal of urology. 2016; 34:49-55.
25. Hsiao WL, Liu L. The role of traditional Chinese herbal medicines in cancer therapy-from TCM theory to mechanistic insights. Planta medica. 2010; 76:1118-1131.
26. Shen J, Zhang D, Zhao Z, Jia L, Zheng D, Liu G, Hao L, Zhang Q, Tian X, Li C, Guo H. Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates. International journal of pharmaceutics. 2013; 456:80-86.
27. Ding C, Zhang Y, Chen H, Wild C, Wang T, White MA, Shen Q, Zhou J. Overcoming synthetic challenges of oridonin A-ring structural diversification: regio-and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Organic letters. 2013; 15:3718-3721.
28. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Ye N, Ester CD, Xiong A, White MA, Shen Q, Zhou J. Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. Journal of medicinal chemistry. 2013; 56:8814-8825.
29. Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo MM, Wu XR, Leung HY, Sansom OJ. beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene. 2011; 30:178-189.
30. Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, Leung HY, Sansom OJ. Ras mutation cooperates with betacatenin activation to drive bladder tumourigenesis. Cell death & disease. 2011; 2:e124.
31. Hirata H, Hinoda Y, Ueno K, Shahryari V, Tabatabai ZL, Dahiya R. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis. 2012; 33:41-48.
32. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell. 2012; 149:1192-1205.
33. Stoehr R, Krieg RC, Knuechel R, Hofstaedter F, Pilarsky C, Zaak D, Schmitt R, Hartmann A. No evidence for involvement of beta-catenin and APC in urothelial carcinomas. International journal of oncology. 2002; 20:905-911.
34. Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ, Dahiya R. Betacatenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. The Journal of urology. 2002; 168:2220-2226.
35. Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, Kavantzas N, Patsouris ES, Noni A, Legaki S, Dimopoulos MA, Bamias A. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. International journal of cancer. 2009; 124:103-108.
36. Zimmerman ZF, Moon RT, Chien AJ. Targeting Wnt pathways in disease. Cold Spring Harbor perspectives in biology. 2012; 4.
37. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nature reviews Cancer. 2014; 14:581-597.
38. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ, Davies FE. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010; 116:250-253.
39. Ding C, Wang L, Chen H, Wild C, Ye N, Ding Y, Wang T, White MA, Shen Q, Zhou J. ent-Kaurane-based regio-and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Organic & biomolecular chemistry. 2014; 12:8442-8452.
40. Ding C, Zhang Y, Chen H, Yang Z, Wild C, Chu L, Liu H, Shen Q, Zhou J. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting groupfree synthesis, enhanced anticancer profile, and improved aqueous solubility. Journal of medicinal chemistry. 2013; 56:5048-5058.
41. Li Q, Dashwood WM, Zhong X, Al-Fageeh M, Dashwood RH. Cloning of the rat beta-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters. Genomics. 2004; 83:231-242.
42. Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou J, Li L, Chen Y, Zhang T, Wang X, Hsieh JT, He D. PI3K/Akt to GSK3beta/beta-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription. Cellular signalling. 2012; 24:2273-2282.
43. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcomebased cut-point optimization. Clinical cancer research. 2004; 10:7252-7259.